Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
Laura W. Dillon, Gege Gui, Kristin Page, et al.
JAMA (2023) Vol. 329, Iss. 9, pp. 745-745
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 15, pp. 1766-1775
Open Access | Times Cited: 66
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
Laura W. Dillon, Gege Gui, Niveditha Ravindra, et al.
JAMA Oncology (2024) Vol. 10, Iss. 8, pp. 1104-1104
Open Access | Times Cited: 16
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 2, pp. 193-202
Open Access | Times Cited: 35
How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan
Blood (2023)
Open Access | Times Cited: 33
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Jad Othman, Nicola Potter, Katya Mokretar, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2066-2072
Open Access | Times Cited: 32
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
Jurjen Versluis, Wael Saber, Harrison Tsai, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 28, pp. 4497-4510
Open Access | Times Cited: 30
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing Soo Tiong, Jenny O’Nions, et al.
Blood (2023) Vol. 143, Iss. 4, pp. 336-341
Open Access | Times Cited: 29
Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia
Simone E. Dekker, Delphine Réa, Jean‐Michel Cayuela, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 25
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Ing Soo Tiong, Devendra Hiwase, Emad Uddin Abro, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 18, pp. 2161-2173
Open Access | Times Cited: 12
Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation
Clara Wienecke, Bennet Heida, Letizia Venturini, et al.
Blood (2024) Vol. 144, Iss. 3, pp. 296-307
Closed Access | Times Cited: 11
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 10
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia
John T. Butler, William M. Yashar, Ronan T. Swords
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
Laura W. Dillon, Jake Higgins, Hassan Nasif, et al.
Haematologica (2023) Vol. 109, Iss. 2, pp. 401-410
Open Access | Times Cited: 18
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML
Brunangelo Falini, Richard Dillon
Blood Cancer Discovery (2023) Vol. 5, Iss. 1, pp. 8-20
Open Access | Times Cited: 16
Measurable residual disease (MRD)-testing in haematological and solid cancers
Junren Chen, Robert Peter Gale, Yu Hu, et al.
Leukemia (2024) Vol. 38, Iss. 6, pp. 1202-1212
Open Access | Times Cited: 6
Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
Luxiang Wang, Chunli Zhang, Shuang Fan, et al.
The Innovation (2023) Vol. 4, Iss. 4, pp. 100461-100461
Open Access | Times Cited: 14
Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
Carlos Jiménez Chillón, Jad Othman, David Taussig, et al.
Blood Advances (2023) Vol. 8, Iss. 2, pp. 343-352
Open Access | Times Cited: 14
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
Niveditha Ravindra, Laura W. Dillon, Gege Gui, et al.
Bone Marrow Transplantation (2024) Vol. 59, Iss. 3, pp. 428-430
Closed Access | Times Cited: 5
Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic Imaging
Shovik Bandyopadhyay, Michael Duffy, Kyung Jin Ahn, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient Outcomes
Yung‐Tsi Bolon, Rasha Atshan, Mariam Allbee‐Johnson, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 9, pp. 921.e1-921.e22
Closed Access | Times Cited: 5
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, et al.
Blood (2025)
Open Access
Editorial: Molecular MRD testing in patients with acute myeloid leukemia
Amanda Blackmon, Michael R. Grunwald
Bone Marrow Transplantation (2025)
Open Access
Measurable Residual Disease in Acute Myeloid Leukaemia
Jacqueline Cloos, Angèle Kelder, Dave de Leeuw, et al.
Cambridge University Press eBooks (2025), pp. 174-192
Closed Access
Page 1 - Next Page

Scroll to top